Use of Pulmonary Vasodilators in Very Preterm Infants
Author Information
Author(s): Bamat Nicolas, Vega Tomas, Huber Matthew, Jensen Erik, Avitabile Catherine, Lorch Scott, Gibbs Kathleen, O’Byrne Michael, Frank David
Primary Institution: The Children’s Hospital of Philadelphia
Hypothesis
To describe common pulmonary vasodilators, exposure timing, and characteristics associated with their use in very preterm infants.
Conclusion
Early inhaled nitric oxide and late sildenafil are used in very preterm infants despite limited evidence.
Supporting Evidence
- 6.3% of infants received pulmonary vasodilators during the study period.
- Early exposure to inhaled nitric oxide was associated with lower gestational age.
- Late exposure to sildenafil was associated with higher grades of bronchopulmonary dysplasia.
Takeaway
Doctors often give special medicines to help the lungs of very tiny babies, but we need to study them more to make sure they really help.
Methodology
Observational study of very preterm infants discharged from U.S. children’s hospitals from 2011 to 2021, identifying pulmonary vasodilator exposures and using multivariable modeling.
Potential Biases
Potential misclassification bias due to reliance on ICD codes for diagnosis and treatment.
Limitations
The study could not determine precise indications for pulmonary vasodilator use and relied on administrative data, which may be subject to misclassification bias.
Participant Demographics
Infants born between 22 and 31 weeks gestational age, with a median length of stay of 67 days.
Statistical Information
P-Value
p<0.001
Confidence Interval
9.2 (7.3–11.7)
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website